Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evgenia Verrou

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Leukemia Research|December 18, 2007
Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?Eirini Katodritou, Evgenia Verrou, Vassiliki Gastari, et al.
Leukemia Research|July 6, 2006
Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosisEvangelos Terpos, Evgenia Verrou, Anastasia Banti, et al.
British Journal of Haematology|August 8, 2006
Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patientsKostas Zervas, Evgenia Verrou, Zisis Teleioudis, et al.
Frontiers in Genetics|April 29, 2024
HLA variations in patients with diffuse large B-cell lymphoma and association with disease risk and prognosis: a case-control studyIoanna Diamanti, Asimina Fylaktou, Evgenia Verrou, et al.
Leukemia Research Reports|August 17, 2021
Chronic myelogenous leukemia occurring in two brothers: The opposite sides of the same coin?Evgenia Verrou, Kyriaki Tsirou, Nikolaos Karampatzakis, et al.
Annals of Hematology|March 22, 2007
Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphomaEirini Katodritou, Evangelos Terpos, Konstantinos Zervas, et al.
American Journal of Hematology|July 16, 2008
Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myelomaEirini Katodritou, Evgenia Verrou, Christina Hadjiaggelidou, et al.
Leukemia Research|June 15, 2007
Successful treatment of extramedullary gastric plasmacytoma with the combination of bortezomib and dexamethasone: first reported caseEirini Katodritou, Charalambos Kartsios, Vassiliki Gastari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
Natural history of osteonecrosis of the jaw in patients with multiple myelomaAshraf Badros, Evangelos Terpos, Eirini Katodritou, et al.
Annals of Hematology|March 22, 2019
Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcomeChristina Hadjiaggelidou, Evdokia Mandala, Evangelos Terpos, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Leukemia Research|December 18, 2007
Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?Eirini Katodritou, Evgenia Verrou, Vassiliki Gastari, et al.
Leukemia Research|July 6, 2006
Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosisEvangelos Terpos, Evgenia Verrou, Anastasia Banti, et al.
British Journal of Haematology|August 8, 2006
Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patientsKostas Zervas, Evgenia Verrou, Zisis Teleioudis, et al.
Frontiers in Genetics|April 29, 2024
HLA variations in patients with diffuse large B-cell lymphoma and association with disease risk and prognosis: a case-control studyIoanna Diamanti, Asimina Fylaktou, Evgenia Verrou, et al.
Leukemia Research Reports|August 17, 2021
Chronic myelogenous leukemia occurring in two brothers: The opposite sides of the same coin?Evgenia Verrou, Kyriaki Tsirou, Nikolaos Karampatzakis, et al.
Annals of Hematology|March 22, 2007
Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphomaEirini Katodritou, Evangelos Terpos, Konstantinos Zervas, et al.
American Journal of Hematology|July 16, 2008
Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myelomaEirini Katodritou, Evgenia Verrou, Christina Hadjiaggelidou, et al.
Leukemia Research|June 15, 2007
Successful treatment of extramedullary gastric plasmacytoma with the combination of bortezomib and dexamethasone: first reported caseEirini Katodritou, Charalambos Kartsios, Vassiliki Gastari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
Natural history of osteonecrosis of the jaw in patients with multiple myelomaAshraf Badros, Evangelos Terpos, Eirini Katodritou, et al.
Annals of Hematology|March 22, 2019
Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcomeChristina Hadjiaggelidou, Evdokia Mandala, Evangelos Terpos, et al.
Pageof 3